Welcome to our dedicated page for Applied DNA Sciences news (Ticker: $APDN), a resource for investors and traders seeking the latest updates and insights on Applied DNA Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Applied DNA Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Applied DNA Sciences's position in the market.
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) has been awarded a contract by HDT Bio for rapid vaccine development, aiming to manufacture mRNA vaccines within 7 days. The project focuses on decentralized vaccine manufacturing to combat infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1993.8%
Tags
-
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) announces a 1-for-20 reverse stock split effective April 25, 2024, to comply with Nasdaq listing requirements. The split reduces outstanding shares from 17.26 million to approximately 863,000, with proportional adjustments to stock options and warrants. The Company's common stock will trade on a split-adjusted basis under symbol 'APDN' on the Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.12%
Tags
-
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) partners with Alphazyme to scale-up manufacturing of Linea RNA polymerase (RNAP) to meet growing demand for Linea IVT platform. The collaboration aims to increase RNAP manufacturing capacity, reduce unit costs of goods, and coincide with the Company's planned initiation of GMP manufacturing for Linea DNA IVT templates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.57%
Tags
Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) will present Linea IVT and Linea DNA platforms at the 24th Annual World Vaccine Congress. Sales team members will be available for meetings during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.08%
Tags
-
Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) announced first-quarter fiscal 2024 financial results. The company is on track to initiate first-phase GMP production capacity for mRNA critical starting materials during the first half of calendar 2024. The initial facility capacity is projected to enable up to $15 million of Linea IVT revenue annually. The company also announced the completion of an equity offering to support the initial phase of the GMP plan and timeline for critical starting materials in the production of mRNA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
-
News
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) will release its first quarter fiscal 2024 financial results on February 8, 2024, after market close. A conference call for analysts and investors will be held the same day at 4:30 p.m. ET to discuss the financial results and recent accomplishments. The call will be accessible via dial-in and live webcast, with a replay available for 7 days. An accompanying slide presentation will be available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) has closed a direct offering of common stock and issued unregistered warrants to certain institutional investors. The company also amended the exercise price and expiration dates of previously issued common stock warrants. The net proceeds from the offering will be used for therapeutic DNA production services and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) has entered into securities purchase agreements with existing institutional investors for the issuance and sale of 5,644,061 shares of common stock at a purchase price of $0.609 per share in a registered direct offering. In a concurrent private placement, the company has also agreed to issue and sell unregistered warrants to purchase up to 11,288,122 shares of its common stock. The warrants have an exercise price of $0.609 per share and will become exercisable on the first trading day after receipt of shareholder approval. Additionally, the company will reduce the exercise price of 3,055,139 common stock warrants previously issued to the investors and extend warrant expiration dates into 2028, subject to approval by the company's stockholders at a stockholder meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
-
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) and Kudo Biotechnology (Kudo Bio) have entered into a joint development agreement to integrate Applied DNA's Linea IVT platform into Kudo Bio's commercial mRNA manufacturing workflows. The agreement aims to optimize mRNA quality, yields, and mitigate contamination by double-stranded RNA (dsRNA) at manufacturing scale. Upon successful completion, the joint workflow is planned for commercial launch in the second half of calendar 2024. The Linea IVT Platform is expected to provide advantages over conventional mRNA manufacturing methods, including the prevention or reduction of dsRNA contamination and reduced mRNA manufacturing turn-around-times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) announced consolidated financial results for its fourth quarter ended September 30, 2023. The company's total revenues were approximately $780 thousand, a decrease from $3.6 million for the same period in the prior fiscal year. Operating loss decreased to $4.2 million for the three-month period ended September 30, 2023, as compared to $4.3 million for the fourth quarter of fiscal 2022. Net loss was $3.6 million for the three-month period ended September 30, 2023, compared to $665 thousand for the fourth quarter of 2022. Cash and cash equivalents stood at $7.2 million on September 30, 2023, compared with $10.8 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.52%
Tags
Applied DNA Sciences, Inc.
Nasdaq:APDN
APDN Rankings
APDN Stock Data
3.53M
13.60M
12.32%
19.23%
1.6%
Cyclic Crude, Intermediate, and Gum and Wood Chemical Manufacturing
Manufacturing
United States of America
STONY BROOK
About APDN
we keep life real and safe by providing botanical-dna based security and authentication solutions and services that protect assets, products, brands, supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.